Correlation Between Inflammatory Factor Levels and Clinical Prognosis in Patients with Myocardial Ischemia-Reperfusion Injury

Abstract

Objective: The aim of this paper is to study how astragaloside IV and the levels of pro-inflammatory cytokines are related to the
severity of myocardial injury in a rat model of myocardial ischemia-reperfusion injury (MIRI), and based on the theoretical basis and experimental data obtained here, optimise the therapeutic protocol. Method: 1. Cellular experiment: The division of the rat-derived cardiomyocyte
cell line H9C2 cells (obtained from the Shanghai Cell Bank) was carried out, and then different concentrations of astragaloside IV (0, 0.1, 0.2
and 0.3 mg/L) were added. After 24 hours of cultivation, the absorbance (OD value) of all wells was measured and the number of viable cells
was determined according to the CCK-8 kit protocol. The first one was chosen for further study because it had good cell viability and strong
anti-inflammatory properties. Animal experiment: Thirty healthy SD rats were randomly distributed among the three groups, which were the
control group, the model group and the astragaloside IV group (observation group). The model group had coronary artery occlusion and thus
was an MIRI model. The astragaloside IV group received astragaloside IV therapy before reperfusion. The control group did not receive intervention. Result: After giving astragaloside IV, the amount of pro-inflammatory markers in the observation group was not statistically different
from that in the model group. In addition, the function of the heart improved more significantly, and the extent of damage to the heart muscle
decreased (P < 0.05). Conclusion: Astragaloside IV is used to reduce inflammation, improve the function of the heart muscle, reduce tissue
damage in rats with myocardial ischemia-reperfusion injury, etc.